Clinical Research Directory

Inclusion and exclusion criteria for healthy subjects were consistent with bioequivalence studies. Inclusion Criteria: 1. Age 18-89 years; 2. ECG meeting the diagnostic criteria for atrial fibrillation; 3. Provide at least one valid blood sample for SNP testing; 4. no contraindication to anticoagulation, blood counts and coagulation times within normal reference values, and negative urine and stool occult blood; 5. not have had any stroke in the 6 months prior to enrollment. Exclusion Criteria: 1. Cardiac ultrasound suggestive of moderate-to-severe mitral stenosis or after mechanical valve replacement; 2. severe hepatic injury or renal insufficiency (estimated glomerular filtration rate \[eGFR\] \<30 mL/(min\*1.73m2)) 3. History of stroke or peripheral arterial embolism during dosing; 4. patients at high risk of bleeding, such as history of bleeding, hematologic disorders, other disorders requiring anticoagulant therapy, peptic ulcer and other bleeding, and blood pressure \>180/110 mmHg; 5. Combination of other serious diseases, such as malignant tumors, severe hepatic and renal insufficiency; 6. history of allergy to dabigatran and warfarin.